The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 22, 2020

Filed:

Jun. 11, 2014
Applicants:

Chugai Seiyaku Kabushiki Kaisha, Tokyo, JP;

National Center of Neurology and Psychiatry, Tokyo, JP;

Inventors:

Takashi Yamamura, Tokyo, JP;

Masakazu Nakamura, Tokyo, JP;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/564 (2006.01); A61K 45/00 (2006.01); C07K 16/28 (2006.01); G01N 33/50 (2006.01);
U.S. Cl.
CPC ...
G01N 33/564 (2013.01); A61K 45/00 (2013.01); C07K 16/2866 (2013.01); G01N 33/5052 (2013.01); C07K 2317/76 (2013.01); G01N 2333/5412 (2013.01); G01N 2333/565 (2013.01); G01N 2333/70596 (2013.01); G01N 2800/285 (2013.01); G01N 2800/52 (2013.01);
Abstract

According to the present invention, the amount of a plasmablast (PB) in a sample of a relapsing-remitting multiple sclerosis (RRMS) patient can be measured, thereby predicting the therapeutic effect of interferon beta (IFN-β) or predicting a RRMS case for which the continuous administration of IFN-β is difficult due to the manifestation of a serious adverse reaction or the aggravation of concomitant immune disorder. In addition, the amount of PB in a sample of a RRMS patient can also be measured, thereby predicting the therapeutic effect of an IL-6 inhibitor in the treatment of RRMS. As a result, a treatment method effective for patients not suitable for IFN-β in the treatment of RRMS can be provided.


Find Patent Forward Citations

Loading…